8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 24, 2026·SEC
Material company update
Mar 3, 2026·SEC
Amylyx Pharmaceuticals, Inc.(AMLX)Earnings, Financials & Key Ratios
AMLX•NASDAQ
Price updated Jun 11, 2026
AboutAmylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$153M+51.3%
- Net Income-$145M+52.0%
- EPS (Diluted)-1.53+65.5%
- ROE-61.59%+39.0%
- ROIC-132.21%
- Debt/Equity0.02+62.3%
AMLX Key Insights
Amylyx Pharmaceuticals, Inc. (AMLX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 27.9% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 38.8% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AMLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AMLX Price & Volume
Amylyx Pharmaceuticals, Inc. (AMLX) stock price & volume — 10-year historical chart
Loading chart...
AMLX Growth Metrics
Amylyx Pharmaceuticals, Inc. (AMLX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM31.41%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM52.41%
Return on Capital
10 Years-308.81%
5 Years-85.29%
3 Years-53.12%
Last Year-64.52%
AMLX Recent Earnings
Amylyx Pharmaceuticals, Inc. (AMLX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 2/12 qtrs (40%)
Q2 2026Latest
May 7, 2026EPS
$0.37
Est $0.34
-8.8%
Revenue
—
Q2 2026
Mar 3, 2026EPS
$0.30
Est $0.31
+3.2%
Revenue
—
Est $52,000
Q4 2025
Nov 6, 2025EPS
$0.37
Est $0.43
+14.0%
Revenue
—
Est $52,000
Q3 2025
Aug 7, 2025EPS
$0.46
Est $0.44
-4.5%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.37vs $0.34-8.8% | — |
| Q2 2026 | Mar 3, 2026 | $0.30vs $0.31+3.2% | —vs $52,000 |
| Q4 2025 | Nov 6, 2025 | $0.37vs $0.43+14.0% | —vs $52,000 |
| Q3 2025 | Aug 7, 2025 | $0.46vs $0.44-4.5% | — |
Based on last 12 quarters of dataView full earnings history →
AMLX Peer Comparison
Amylyx Pharmaceuticals, Inc. (AMLX) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IONS | 12.2B | 73.82 | -31.02 | 33.87% | -30.87% | -58.57% | 5.35 | |
 BIIB | 29.52B | 199.96 | 22.65 | 1.39% | 13.92% | 7.55% | 0.38 | |
 MDGL | 10.93B | 474.28 | -36.91 | 432.05% | -27.32% | -50.15% | 0.59 | |
 ACAD | 3.66B | 21.39 | 9.34 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PRTA | 432.44M | 8.26 | -1.82 | -92.84% | -260.92% | -49.88% | 0.05 | |
 AGEN | 141.17M | 3.39 | -997.06 | 10.37% | 52.16% | |||
 ARVN | 457.46M | 7.09 | -5.54 | -0.3% | -247.54% | -44.39% | 0.02 | |
 SRRK | 5.36B | 44.69 | -13.58 | -163.52% | 0.44 |
Compare AMLX vs Peers
Amylyx Pharmaceuticals, Inc. (AMLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AMLX Income Statement
Amylyx Pharmaceuticals, Inc. (AMLX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.43M | 650K | 0 | 22.23M | 380.79M | 87.37M | 0 | 0 |
Revenue Growth % | - | -54.42% | -100% | - | 1612.94% | -77.06% | -100% | 100% |
Cost of Goods Sold | 11.9M | 24.59M | 0 | 2.99M | 25.44M | 42.16M | 525K | 20.2M |
COGS % of Revenue | 834.43% | 3783.69% | - | 13.46% | 6.68% | 48.25% | - | - |
Gross Profit | -10.47M▲ 0% | -23.94M▼ 128.6% | 0▲ 100.0% | 19.24M▲ 0% | 355.35M▲ 1747.2% | 45.22M▼ 87.3% | -525K▼ 101.2% | -20.2M▲ 0% |
Gross Margin % | -734.43% | -3683.69% | - | 86.54% | 93.32% | 51.75% | - | - |
Gross Profit Growth % | - | -128.63% | 100% | - | 1747.2% | -87.28% | -101.16% | - |
Operating Expenses | 13.55M | 15.06M | 82.69M | 220.58M | 316.54M | 359.95M | 152.77M | 139.16M |
OpEx % of Revenue | 950.49% | 2317.08% | - | 992.25% | 83.13% | 411.97% | - | - |
Selling, General & Admin | 3.08M | 15.06M | 38.93M | 127.13M | 188.36M | 114.33M | 62.89M | 63.37M |
SG&A % of Revenue | 216.06% | 2317.08% | - | 571.88% | 49.47% | 130.86% | - | - |
Research & Development | 11.9M | 24.59M | 44.04M | 93.45M | 128.19M | 104.08M | 90.4M | 95.65M |
R&D % of Revenue | 834.43% | 3783.69% | - | 420.38% | 33.66% | 119.13% | - | - |
Other Operating Expenses | -1.43M | -24.59M | -285K | 0 | 0 | 141.53M | 0 | -1000K |
Operating Income | -13.55M▲ 0% | -39.01M▼ 187.8% | -82.69M▼ 112.0% | -201.34M▼ 143.5% | 38.8M▲ 119.3% | -314.73M▼ 911.1% | -153.29M▲ 51.3% | -159.27M▲ 0% |
Operating Margin % | -950.49% | -6000.77% | - | -905.72% | 10.19% | -360.22% | - | - |
Operating Income Growth % | - | -187.77% | -111.99% | -143.49% | 119.27% | -911.12% | 51.29% | - |
EBITDA | 0 | -39M | -82.64M | -200.85M | 39.89M | -313.83M | -152.77M | -158.8M |
EBITDA Margin % | - | -6000.62% | - | -903.53% | 10.48% | -359.19% | - | - |
EBITDA Growth % | - | - | -111.87% | -143.06% | 119.86% | -886.73% | 51.32% | 23.21% |
D&A (Non-Cash Add-back) | 13.55M | 1K | 52K | 487K | 1.09M | 904K | 525K | 467K |
EBIT | -12.44M | -39.01M | -82.69M | -201.34M | 38.8M | -291.88M | -144.69M | -150.66M |
Net Interest Income | -1.1M | -2.27M | 36K | 4.29M | 16.16M | 13.81M | 9.3M | 9.64M |
Interest Income | 176K | 14K | 36K | 4.29M | 16.16M | 13.81M | 9.3M | 9.64M |
Interest Expense | 1.28M | 2.29M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -162K | -3.27M | -5.24M | 3.74M | 15.49M | 12.6M | 8.6M | 9.2M |
Pretax Income | -13.72M▲ 0% | -42.28M▼ 208.3% | -87.93M▼ 108.0% | -197.6M▼ 124.7% | 54.3M▲ 127.5% | -302.14M▼ 656.5% | -144.69M▲ 52.1% | -150.07M▲ 0% |
Pretax Margin % | -961.85% | -6504.62% | - | -888.89% | 14.26% | -345.81% | - | - |
Income Tax | 0 | 0 | 0 | 774K | 5.03M | -393K | 46K | 46K |
Effective Tax Rate % | 0% | 0% | 0% | -0.39% | 9.26% | 0.13% | -0.03% | -0.03% |
Net Income | -14.82M▲ 0% | -42.28M▼ 185.4% | -87.93M▼ 108.0% | -198.38M▼ 125.6% | 49.27M▲ 124.8% | -301.74M▼ 712.4% | -144.74M▲ 52.0% | -150.11M▲ 0% |
Net Margin % | -1038.99% | -6504.62% | - | -892.38% | 12.94% | -345.36% | - | - |
Net Income Growth % | - | -185.37% | -107.97% | -125.6% | 124.84% | -712.41% | 52.03% | 31.41% |
Net Income (Continuing) | -13.72M | -42.28M | -87.93M | -198.38M | 49.27M | -301.74M | -144.74M | -150.11M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.26▲ 0% | -0.79▼ 203.8% | -1.52▼ 92.4% | -2.98▼ 96.1% | 0.70▲ 123.5% | -4.43▼ 732.9% | -1.53▲ 65.5% | -1.36▲ 0% |
EPS Growth % | - | -203.85% | -92.41% | -96.05% | 123.49% | -732.86% | 65.46% | 52.41% |
EPS (Basic) | -0.26 | -0.79 | -1.52 | -2.98 | 0.73 | -4.43 | -1.53 | - |
Diluted Shares Outstanding | 56.47M | 56.47M | 57.86M | 66.51M | 69.99M | 68.14M | 94.57M | 110.56M |
Basic Shares Outstanding | 56.47M | 56.47M | 57.86M | 66.51M | 67.23M | 68.14M | 94.57M | 110.56M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
AMLX Balance Sheet
Amylyx Pharmaceuticals, Inc. (AMLX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 3.2M | 13.64M | 104.95M | 382.13M | 464.67M | 189.43M | 323.67M | 285.02M |
Cash & Short-Term Investments | 3.06M | 12.88M | 96.12M | 346.94M | 371.36M | 176.5M | 316.98M | 279.77M |
Cash Only | 3.06M | 12.88M | 50.19M | 62.53M | 170.2M | 77.39M | 226.65M | 229.14M |
Short-Term Investments | 0 | 0 | 45.93M | 284.42M | 201.16M | 99.11M | 90.33M | 50.63M |
Accounts Receivable | 0 | 0 | 0 | 15.31M | 40.05M | 447K | 88K | 0 |
Days Sales Outstanding | - | - | - | 251.31 | 38.39 | 1.87 | - | - |
Inventory | 0 | 0 | 0 | 9.77M | 38.32M | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | 1.19K | 549.82 | - | - | - |
Other Current Assets | 26K | 0 | 3.44M | 10.11M | 14.93M | 12.48M | 6.6M | 5.26M |
Total Non-Current Assets | 18K | 465K | 663K | 9.32M | 52.79M | 4.2M | 8.97M | 8.58M |
Property, Plant & Equipment | 0 | 151K | 474K | 8.13M | 6.41M | 2.73M | 5.49M | 5.09M |
Fixed Asset Turnover | - | 4.30x | - | 2.73x | 59.40x | 31.98x | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 189K | 0 | 0 | 0 | 0 | 0 | 2.43M |
Other Non-Current Assets | 18K | 125K | 189K | 1.19M | 46.38M | 1.47M | 3.48M | 3.49M |
Total Assets | 3.22M▲ 0% | 14.1M▲ 338.0% | 105.61M▲ 648.8% | 391.45M▲ 270.6% | 517.45M▲ 32.2% | 193.63M▼ 62.6% | 332.64M▲ 71.8% | 293.6M▲ 0% |
Asset Turnover | 0.44x | 0.05x | - | 0.06x | 0.74x | 0.45x | - | 0.00x |
Asset Growth % | - | 338.01% | 648.82% | 270.64% | 32.19% | -62.58% | 71.79% | 108.71% |
Total Current Liabilities | 4.53M | 7.33M | 17.4M | 46.61M | 82.04M | 28.41M | 22.69M | 15.97M |
Accounts Payable | 2.19M | 3.61M | 4.37M | 6.26M | 22.06M | 2.94M | 3.52M | 3.53M |
Days Payables Outstanding | 67.33 | 53.62 | - | 763.05 | 316.51 | 25.45 | 2.45K | 70.83 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 1.26M | 1.16M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 652K | 0 | 4.28M | 15.23M | 40.93M | 9.99M | 17.91M | 11.28M |
Current Ratio | 0.71x | 1.86x | 6.03x | 8.20x | 5.66x | 6.67x | 14.27x | 17.85x |
Quick Ratio | 0.71x | 1.86x | 6.03x | 7.99x | 5.20x | 6.67x | 14.27x | 17.85x |
Cash Conversion Cycle | - | - | - | 679.61 | 271.7 | - | - | - |
Total Non-Current Liabilities | 24.05M | 73.5M | 239.39M | 4.24M | 1.98M | 463K | 4.7M | 4.48M |
Long-Term Debt | 14.93M | 1.43M | 0 | 0 | 0 | 0 | 4.7M | 4.48M |
Capital Lease Obligations | 0 | 0 | 0 | 4.24M | 1.98M | 463K | 0 | 10.25M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9.11M | 72.06M | 239.39M | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 28.58M | 80.83M | 256.78M | 50.85M | 84.02M | 28.87M | 27.39M | 20.44M |
Total Debt | 14.93M | 1.43M | 0 | 6.28M | 4.24M | 1.98M | 5.96M | 5.63M |
Net Debt | 11.87M | -11.45M | -50.19M | -56.25M | -165.96M | -75.41M | -220.69M | -223.5M |
Debt / Equity | - | - | - | 0.02x | 0.01x | 0.01x | 0.02x | 0.02x |
Debt / EBITDA | - | - | - | - | 0.11x | - | - | -0.04x |
Net Debt / EBITDA | - | - | - | - | -4.16x | - | - | 1.41x |
Interest Coverage | -9.75x | -17.05x | - | - | - | - | - | - |
Total Equity | -25.36M▲ 0% | -66.72M▼ 163.1% | -151.17M▼ 126.6% | 340.61M▲ 325.3% | 433.43M▲ 27.3% | 164.76M▼ 62.0% | 305.26M▲ 85.3% | 273.16M▲ 0% |
Equity Growth % | - | -163.14% | -126.55% | 325.32% | 27.25% | -61.99% | 85.27% | 154.34% |
Book Value per Share | -0.45 | -1.18 | -2.61 | 5.12 | 6.19 | 2.42 | 3.23 | 2.47 |
Total Shareholders' Equity | -25.36M | -66.72M | -151.17M | 340.61M | 433.43M | 164.76M | 305.26M | 273.16M |
Common Stock | 1K | 1K | 1K | 7K | 7K | 7K | 11K | 11K |
Retained Earnings | -25.63M | -67.91M | -155.84M | -354.22M | -304.95M | -606.69M | -751.43M | -792.71M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -72.06M | 9K | -86K | 197K | -92K | 404K | 240K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AMLX Cash Flow Statement
Amylyx Pharmaceuticals, Inc. (AMLX) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -10.69M | -36.7M | -74.8M | -179.87M | 11.92M | -167.65M | -123.34M | -120.4M |
Operating CF Margin % | -749.44% | -5645.69% | - | -809.14% | 3.13% | -191.88% | - | - |
Operating CF Growth % | - | -243.38% | -103.83% | -140.47% | 106.63% | -1506.55% | 26.43% | 149.13% |
Net Income | -13.72M | -42.28M | -87.93M | -198.38M | 49.27M | -301.74M | -144.74M | -150.11M |
Depreciation & Amortization | 0 | 1K | 52K | 487K | 1.09M | 904K | 525K | 467K |
Stock-Based Compensation | 108K | 243K | 3.14M | 21.71M | 37.16M | 33.04M | 27.64M | 20.81M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -583K | 2.74M | 5.35M | -2.06M | -9.94M | 145.99M | -5.7M | 5.57M |
Working Capital Changes | 3.5M | 2.6M | 4.59M | -1.64M | -65.66M | -45.83M | -1.08M | 2.86M |
Change in Receivables | 0 | 0 | -144K | -15.31M | -24.74M | 39.6M | 383K | 170K |
Change in Inventory | 0 | 0 | 0 | -9.77M | -73.13M | -9.25M | 0 | 0 |
Change in Payables | 1.28M | 1.42M | 670K | 1.85M | 15.88M | -19.1M | 580K | -1.28M |
Cash from Investing | 0 | -151K | -46.41M | -238.99M | 92.05M | 75.65M | 14.04M | 93.96M |
Capital Expenditures | 0 | -151K | -353K | -2.53M | -1.24M | -157K | -138K | -4.13M |
CapEx % of Revenue | - | 23.23% | - | 11.36% | 0.33% | 0.18% | - | - |
Acquisitions | 0 | 0 | 0 | 236.46M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -236.46M | 0 | -36.2M | 0 | 0 |
Cash from Financing | 668K | 46.82M | 158.51M | 431.79M | 3.54M | 348K | 257.03M | 194.58M |
Debt Issued (Net) | 641K | 16.82M | 25.9M | 0 | 0 | 0 | 0 | 191.11M |
Equity Issued (Net) | 27K | 29.96M | 135M | 432.45M | 6.86M | 2.13M | 260.39M | 266.58M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 48K | -2.39M | -658K | -3.31M | -1.78M | -3.36M | -263.11M |
Net Change in Cash | 3.09M▲ 0% | 9.97M▲ 222.7% | 37.31M▲ 274.1% | 12.87M▼ 65.5% | 107.67M▲ 737.0% | -92.08M▼ 185.5% | 148.8M▲ 261.6% | 169.37M▲ 0% |
Free Cash Flow | -10.69M▲ 0% | -36.85M▼ 244.8% | -75.15M▼ 104.0% | -182.4M▼ 142.7% | 10.68M▲ 105.9% | -167.8M▼ 1671.5% | -123.48M▲ 26.4% | -120.53M▲ 0% |
FCF Margin % | -749.44% | -5668.92% | - | -820.5% | 2.8% | -192.06% | - | - |
FCF Growth % | - | -244.79% | -103.95% | -142.7% | 105.85% | -1671.49% | 26.41% | 41.8% |
FCF per Share | -0.19 | -0.65 | -1.30 | -2.74 | 0.15 | -2.46 | -1.31 | -1.09 |
FCF Conversion (FCF/Net Income) | 0.72x | 0.87x | 0.85x | 0.91x | 0.24x | 0.56x | 0.85x | 0.80x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 27K | 0 | 708K | 0 | 0 |
AMLX Key Ratios
Amylyx Pharmaceuticals, Inc. (AMLX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -209.43% | 12.73% | -100.88% | -61.59% | -55.69% |
| Return on Invested Capital (ROIC) | - | - | -363.87% | 10.55% | -132.31% | -132.21% | -131.73% |
| Gross Margin | -3683.69% | - | 86.54% | 93.32% | 51.75% | - | - |
| Net Margin | -6504.62% | - | -892.38% | 12.94% | -345.36% | - | - |
| Debt / Equity | - | - | 0.02x | 0.01x | 0.01x | 0.02x | 0.02x |
| Interest Coverage | -17.05x | - | - | - | - | - | - |
| FCF Conversion | 0.87x | 0.85x | 0.91x | 0.24x | 0.56x | 0.85x | 0.80x |
| Revenue Growth | -54.42% | -100% | - | 1612.94% | -77.06% | -100% | 100% |
Related:AMLX Dividend History·AMLX Revenue History·AMLX Price History·AMLX P/E History·AMLX Financial Ratios·AMLX Institutional Holders
AMLX SEC Filings & Documents
Amylyx Pharmaceuticals, Inc. (AMLX) SEC filings — annual & quarterly reports (10-K, 10-Q)
AMLX Frequently Asked Questions
Amylyx Pharmaceuticals, Inc. (AMLX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Amylyx Pharmaceuticals, Inc. (AMLX) saw revenue decline by 100.0% over the past year.
Amylyx Pharmaceuticals, Inc. (AMLX) reported a net loss of $150.1M for fiscal year 2025.
Dividend & Returns
Amylyx Pharmaceuticals, Inc. (AMLX) has a return on equity (ROE) of -61.6%. Negative ROE indicates the company is unprofitable.
Amylyx Pharmaceuticals, Inc. (AMLX) had negative free cash flow of $120.5M in fiscal year 2025, likely due to heavy capital investments.